# HHC Has Its Own Schedule I Code Now, and a Second Federal Deadline Lands in November > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/is-hhc-legal-dea-schedule-i-drug-code/ > **Published:** 2026-09-13T10:54:56-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:45:03-04:00 > **Clinical Summary:** Is HHC legal? DEA gave hexahydrocannabinol its own Schedule I drug code in May 2026, and a separate hemp statute reaches it on November 12, 2026. --- CED Clinical Relevance #90Exceptional Clinical RelevancePatients buy HHC believing it is legal hemp and dose it without knowing what is in the package. Two separate federal actions now bear on it, with different dates, and clinicians need the timeline straight before they can counsel anyone accurately. On May 4, 2026 the DEA gave hexahydrocannabinol its own Schedule I drug code. The agency’s position is that the listing changes paperwork rather than status, because HHC was controlled as a tetrahydrocannabinol before the rule existed. The larger change for patients is a statutory one arriving this November. Clinical Insight | CED Clinic The DEA published a final rule assigning hexahydrocannabinol the drug code 7220 and listing it specifically in Schedule I. Before the rule, HHC was controlled under the general tetrahydrocannabinols code 7370. The agency described the amendment as technical and said it makes no substantive difference in HHC’s status. Running alongside it is a statute that matters more for what is on shelves. Section 781 of the November 2025 appropriations law narrows the federal definition of hemp, and the exclusion covering cannabinoids that a cannabis plant cannot naturally produce takes effect November 12, 2026. HHC sits squarely in that category under the government’s own reading. HHCCannabis PolicyHemp LawPatient SafetyFederal Regulation AudiencePatients, caregivers, clinicians, and hemp retail consumersPrimary TopicFederal control status of hexahydrocannabinol and what changed in 2026Source[Read the full source](https://www.federalregister.gov/documents/2026/05/04/2026-08595/specific-listing-for-hexahydrocannabinol-a-currently-controlled-schedule-i-substance) Why This Matters The hemp-derived intoxicant market grew on the argument that the 2018 Farm Bill’s hemp definition swept in anything made from a hemp molecule. Patients absorbed that argument as fact. A person buying an HHC vape at a gas station generally believes they are buying a legal product, and some believe they are buying a medical one. Neither the pharmacology nor the law supported that confidence. What has changed in 2026 is that both the enforcement infrastructure and the statutory text are catching up, on two different clocks, and anyone advising patients should know which clock is which. What the DEA Rule Says and What It Changes The rule, *Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance*, was published May 4, 2026 at 91 FR 23913, Federal Register document 2026-08595, under docket DEA-1632. It amends 21 CFR 1308.11(d) by adding paragraph (115) and assigns HHC the drug code 7220. It took effect on publication. The title carries the government’s whole argument. HHC is described as a currently controlled substance, not a newly controlled one. The DEA’s position is that HHC met the definition of tetrahydrocannabinols under the Controlled Substances Act and has been controlled under the general code 7370, so the specific listing is administrative housekeeping. The agency stated that the rule makes no substantive difference in HHC’s status. The practical function of a discrete code is enforcement and accounting. It lets the agency set aggregate production quotas and individual manufacturing and procurement quotas for registered handlers, and it lets tracking and prosecution reference HHC directly rather than through a category. Why Notice and Comment Was Skipped The DEA did not open the rule for public comment. It invoked 5 U.S.C. 553(b)(B), the exception that permits an agency to forgo notice and comment when the process would be unnecessary, and characterized the action as a minor or merely technical amendment with no substantive change to HHC’s controlled status. It also made the rule effective immediately, saying a delay could cause confusion about regulatory status. That reasoning is internally consistent and also contestable. If HHC was controlled before, a code assignment is bookkeeping. If it was not, then the rule is the operative act and the procedural shortcut is doing real work. Hemp industry litigants have pressed the second reading, and this is the seam any future challenge runs along. For a patient, the procedural question is secondary. The enforcement posture of the federal government toward HHC is not ambiguous regardless of how the rule was adopted. The Legal Argument, Stated Precisely The 2018 Farm Bill excluded hemp, meaning Cannabis sativa L. with no more than 0.3 percent delta-9 THC by dry weight, from the Controlled Substances Act, including the tetrahydrocannabinols in that material. The industry reading was that a molecule made from a hemp-derived starting material inherits the exemption. The DEA reads the exemption as covering what the plant produces, not what a laboratory makes from it. The rule states the position directly: tetrahydrocannabinols produced through chemical conversion, even when hemp derived, are considered synthetically produced for purposes of the Controlled Substances Act. The agency applied that reasoning to HHC earlier, in an April 3, 2024 letter from Terrence L. Boos, chief of the Drug and Chemical Evaluation Section, to the Louisiana Department of Health. That letter concluded that HHC does not occur naturally in the Cannabis sativa L. plant and can only be obtained synthetically, and therefore does not fall under the definition of hemp. It also noted that the determination could change if scientific evidence establishing natural occurrence emerged. The Deadline That Matters More Than the Drug Code Section 781 of Public Law 119-37, the appropriations act signed November 12, 2025, rewrote the federal hemp definition. It replaces the delta-9 threshold with a 0.3 percent total THC standard inclusive of THCA, adds a 0.4 milligram total THC per container cap on finished products, and excludes products containing cannabinoids that a Cannabis sativa L. plant cannot naturally produce, along with cannabinoids that the plant could produce but that were synthesized or manufactured outside it. The changes carried a one year delay to November 12, 2026. On September 2, 2026, the president signed H.R. 6500, the Continuing Appropriations and Extensions Act, 2027. Section 2019 of that law postpones most of the Section 781 amendments to December 11, 2026. It does not postpone the exclusion for cannabinoids that cannot be naturally produced by the plant. That category stays on the original November 12, 2026 schedule. Under the government’s own position that HHC cannot be obtained except synthetically, HHC falls in the category that was not delayed. A patient tracking this needs two dates, not one, and the earlier date is the one that reaches HHC. What Is Actually in an HHC Product Pharmacology is where the clinical objection sits, independent of any legal question. HHC is produced by hydrogenating THC, and hydrogenation creates a stereocenter. Commercial HHC is not one molecule but a mixture of epimers, and the two forms do not behave identically at the CB1 receptor. Forensic data make the point concretely. A study in *Drug Testing and Analysis* examined 1,186 cannabis-type samples seized in Poland between 2022 and 2024 and found semisynthetic cannabinoids in 113 of them, with HHC the predominant compound. HHC appeared consistently as a mixture of two epimers, with the 9R form prevailing at a typical ratio between 2.0 and 2.8 to 1. In roughly 60 percent of cases the material had been applied to plant matter with low THC content, which the authors read as deliberate enrichment of otherwise weak material. The same paper documents why testing does not rescue the situation. Gas chromatography can degrade acetate forms, ultraviolet detection struggles to separate compounds with similar spectra, and high resolution mass spectrometry cannot fully distinguish structural or stereoisomeric forms. A certificate of analysis on an HHC product is reporting a number whose underlying identity is genuinely hard to pin down. How to Counsel a Patient Who Has Been Using HHC Start without accusation. Most people using HHC were told it was legal hemp, and many arrived at it because licensed access was inconvenient, expensive, or unavailable in their state. Treating that as a compliance failure rather than an access problem ends the conversation. The clinically useful questions are the ordinary ones. What is the product, how much, how often, by what route, and alongside which medications. HHC is a CB1 agonist, so the interaction, impairment, and cardiovascular considerations that apply to THC apply here, with the added uncertainty that the delivered dose is unverifiable. Then the practical point. Whatever a patient concludes about federal enforcement risk, the product quality argument stands on its own. A licensed medical or adult-use supply chain has mandatory testing, defined cannabinoid content, child-resistant packaging, and a clinician who can see the whole medication list. The hemp intoxicant market has none of that, which is the reason to move, more than the drug code is. Regulatory SnapshotActionDEA final rule: Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I SubstanceCitation91 FR 23913; Federal Register document 2026-08595; docket DEA-1632Published and EffectiveMay 4, 2026, effective on publicationRegulatory ChangeAmends 21 CFR 1308.11(d) by adding paragraph (115)Drug Code7220, specific to HHC; previously controlled under 7370, tetrahydrocannabinolsChemical Name6,6,9-trimethyl-3-pentyl-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-1-olInternational TriggerUN Commission on Narcotic Drugs placed HHC in Schedule II of the 1971 Convention at its 68th session, March 2025; DEA notified by letter dated June 9, 2025Interagency StepsDEA letter to HHS October 9, 2025; HHS response December 3, 2025 confirming no approved NDAs or INDs and concurring with the listingRulemaking ProcedureNotice and comment waived as unnecessary under 5 U.S.C. 553(b)(B); described as a minor or merely technical amendmentPractical EffectEnables aggregate production quotas and individual manufacturing and procurement quotas; DEA states no substantive change in control statusSeparate Statutory DeadlineSection 781 exclusion for cannabinoids not naturally producible by Cannabis sativa L. takes effect November 12, 2026; most other Section 781 changes were moved to December 11, 2026 by H.R. 6500, signed September 2, 2026 How Strong Is This Evidence? This is a primary regulatory document rather than a scientific one, and it should be read as such. The Federal Register text states the agency’s legal position, the procedural authority it relied on, and the effective date. Those facts are not in dispute and do not require interpretation. What the document cannot settle is whether a reviewing court agrees with the DEA’s construction of the hemp exemption. An agency’s stated reading of a statute is authoritative until it is not, and hemp litigants have challenged this construction. The enforcement reality and the final legal answer are separate things, and only the first is settled today. Where This Paper Deserves Skepticism The technical amendment framing does real work in this rule, and it deserves scrutiny. Waiving notice and comment on the ground that nothing substantive is changing presumes the conclusion that HHC was already controlled, which is precisely the question industry contests. A challenger would argue the agency used a procedural shortcut to settle a substantive dispute. The DEA’s factual premise also carries a caveat the agency itself wrote down. The 2024 letter said the determination rests on HHC not occurring naturally in the plant and could change if evidence to the contrary emerged. Reporting that treats natural occurrence as conclusively resolved is overstating a position the agency stated conditionally. What This Paper Does Not Show This rule does not create a new prohibition, according to the agency, and it does not resolve the litigation over whether chemically converted cannabinoids fall inside the hemp exemption. It does not address delta-8 THC, THC-O, THCP, or any other converted cannabinoid, each of which has its own record. It also says nothing about state law. States vary widely in how they treat HHC and other hemp intoxicants, and a substance controlled federally can still be regulated, banned, or tolerated differently at the state level. A patient asking what applies to them needs a state answer as well as a federal one. How This Fits With the Broader Clinical Conversation The pattern here has repeated since 2019. A definitional gap opens, manufacturers move into it, products reach retail with no testing requirement, regulators respond slowly and inconsistently, and the eventual correction arrives after several years of unsupervised consumption. Delta-8 ran this course first. HHC ran it second. What is different in 2026 is that Congress, rather than an agency, has rewritten the definition. Section 781 does not depend on how the DEA construes the word derived, because it names synthesized and manufactured cannabinoids in the statute. That is a more durable fix than an agency letter, and it is the reason the November date matters more to the market than the drug code does. Dr. Caplan’s Take None of this surprises me. The claim that HHC was legal hemp rested on reading one sentence of the Farm Bill in isolation and ignoring the rest of the controlled substances framework. It grew because enforcement was slow, not because the legal theory was strong. But the legal question is not what concerns me most. I have spent years looking at products patients bring in from smoke shops and hemp retailers, and the recurring feature is that nobody in the chain can tell me what is in the package. Not the ratio, not the isomer mix, not the residual solvents from the conversion step, not the actual milligrams per serving. When the forensic literature says the analytical instruments themselves struggle to separate these stereoisomers, the certificate of analysis on the box is not reassurance. The people using these products are not reckless. They are usually trying to solve a real problem with the access they have. My argument to them is not that they broke a rule. It is that they are dosing something whose identity nobody has established, and that we built an entire field of cannabis medicine specifically to stop doing that. Clinical Bottom Line HHC now has its own Schedule I drug code, and the DEA’s position is that this formalizes control that already existed rather than creating it. The more consequential date is November 12, 2026, when the statutory exclusion for cannabinoids a cannabis plant cannot naturally produce takes effect and is not covered by the delay Congress passed in September. Patients using HHC should have that exposure documented and should be offered a regulated alternative. What a Careful Reader Should Take Away Hold two dates and one distinction. May 4, 2026 was an administrative listing. November 12, 2026 is a statutory exclusion that reaches synthesized cannabinoids and was not postponed. The distinction is between a rule that says HHC has been controlled and a law that says a product containing it is not hemp. Those are different mechanisms arriving at the same place. Evidence Interpretation Guide Table of Contents - [Telling a scheduling action apart from a statutory change](#Telling_a_scheduling_action_apart_from_a_statutory_change) - [One Drug Code, Eight Perspectives](#One_Drug_Code_Eight_Perspectives)[What this means if HHC is in your cabinet](#What_this_means_if_HHC_is_in_your_cabinet) - [Ask by product name, not by category](#Ask_by_product_name_not_by_category) - [The procedural shortcut is doing substantive work](#The_procedural_shortcut_is_doing_substantive_work) - [Coverage keeps merging two separate federal actions](#Coverage_keeps_merging_two_separate_federal_actions) - [This is the delta-8 sequence, repeated](#This_is_the_delta-8_sequence_repeated) - [What a regulated alternative offers](#What_a_regulated_alternative_offers) - [Watch the litigation and the November date](#Watch_the_litigation_and_the_November_date) - [Access is the pressure creating the market](#Access_is_the_pressure_creating_the_market) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## Telling a scheduling action apart from a statutory change The Research QuestionWhat is the federal control status of hexahydrocannabinol, and which federal actions in 2025 and 2026 changed how that status is enforced?The Patient QuestionI have been buying HHC gummies at a hemp shop. Is that legal, and is it safe?The Bottom LineThe DEA says HHC has been Schedule I and now has its own code. Separately, a statute excludes synthesized cannabinoids from the hemp definition starting November 12, 2026. The clinical objection, that nobody can verify what is in the product, is independent of both. CED Perspective Lens ## One Drug Code, Eight Perspectives A regulatory action read from the angles that matter to a patient, a clinician, and a court. Lens OverviewDEA assigned HHC the Schedule I drug code 7220 on May 4, 2026, calling the change technical. A separate statutory exclusion for cannabinoids a cannabis plant cannot naturally produce takes effect November 12, 2026. #### What this means if HHC is in your cabinet The federal government’s position is that HHC has been a Schedule I substance and now has a specific code. Your practical exposure depends heavily on your state’s law, which varies a great deal, and on whether you are buying, carrying, or selling. The more immediate issue is that you cannot verify what you have been taking. Tell your clinician about it the same way you would report any other substance, and ask what a regulated alternative would look like where you live. Lens takeawayReport it to your clinician, then ask about a supply chain that can tell you what is in the package. #### Ask by product name, not by category Patients who say they do not use cannabis will sometimes report HHC, delta-8, or THCP if asked by name, because they classify those as hemp products rather than cannabis. The intake question has to be specific to surface the exposure. Once disclosed, treat it as a CB1 agonist of unverified dose. Interaction review, impairment counseling, and perioperative disclosure apply, with less certainty about the actual exposure than you would have with a tested product. Lens takeawayName the compounds on intake or you will not hear about them. #### The procedural shortcut is doing substantive work Waiving notice and comment rests on the premise that nothing is changing, which assumes the answer to the question industry has contested for years. If HHC was not already controlled, the rule is the operative act and the shortcut is harder to defend. The agency’s own 2024 determination was stated conditionally, resting on HHC not occurring naturally and open to revision if evidence changed. That is a weaker foundation than the confident framing in most coverage. Lens takeawayThe rule’s confidence exceeds the certainty of the premise it stands on. #### Coverage keeps merging two separate federal actions The drug code rule and the statutory hemp redefinition are distinct instruments with distinct dates and distinct mechanisms. Reporting that treats the May rule as the thing that ends HHC sales is conflating them. The September 2026 extension law compounds the confusion by moving most, and only most, of the statutory deadline. The exclusion that reaches synthesized cannabinoids was left on the earlier date. Lens takeawayTwo instruments, three dates. Get them straight before advising anyone. #### This is the delta-8 sequence, repeated The 2018 hemp definition opened a gap, delta-8 filled it first, regulators responded through letters and state-level bans, and years passed before any durable federal answer. HHC followed the same route with a shorter runway. The lesson drawn across both is that definitional loopholes close slowly, and the interval is spent by consumers rather than by regulators. Lens takeawayThe pattern is the story. HHC is the second iteration, not the first. #### What a regulated alternative offers A licensed medical or adult-use product comes with mandatory laboratory testing, stated cannabinoid content, child-resistant packaging, age verification at sale, and a traceable chain back to the cultivator. None of that guarantees a clinical benefit. It guarantees that the dose being discussed is a real number, which is the precondition for any clinical conversation at all. Lens takeawayRegulation does not make a product work. It makes the dose knowable. #### Watch the litigation and the November date Two things determine what happens next: whether courts accept the DEA’s construction of the hemp exemption, and how the Section 781 exclusion is enforced once it takes effect. The second is likely to reshape retail faster than the first. Other converted cannabinoids, including delta-10 and THCP, sit in the same statutory category and face the same question. Lens takeawayThe statute, not the drug code, is what will change what is on the shelf. #### Access is the pressure creating the market The hemp intoxicant market grew fastest in states with restrictive or absent medical cannabis programs. Treating that as purely a compliance failure misreads it. Demand routed around the regulated system because the regulated system was unavailable. Closing the definitional gap without addressing access moves consumption rather than reducing it, which is a predictable outcome worth naming in advance. Lens takeawayEnforcement without access relocates the problem instead of solving it. Related Reading at CED ClinicContinue exploring the evidence[Congress Sends Hemp Deadline Extension to the President](https://cedclinic.com/new-federal-hemp-law-2026-what-changes-and-when/) The current state of the statutory hemp deadlines, including which provisions moved to December 11 and which did not. [Check the dates](https://cedclinic.com/new-federal-hemp-law-2026-what-changes-and-when/)[Pediatric Cannabis Poisoning Calls Rose 3,307% in 25 Years](https://cedclinic.com/pediatric-cannabis-poisoning-national-poison-center-trend-2000-2024/) National poison center trend data on pediatric cannabis exposures, and why packaging and age verification are not paperwork issues. [See the exposure data](https://cedclinic.com/pediatric-cannabis-poisoning-national-poison-center-trend-2000-2024/)[Keeping Pace with Semi-Synthetic Cannabinoids](https://cedclinic.com/keeping-pace-with-semi-synthetic-cannabinoids-indias-regulatory-challenge/) How other jurisdictions are handling the same class of chemically converted cannabinoids, HHC included. [Compare approaches](https://cedclinic.com/keeping-pace-with-semi-synthetic-cannabinoids-indias-regulatory-challenge/) Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) ## Frequently Asked Questions Is HHC legal under federal law? The DEA’s position is that hexahydrocannabinol is a Schedule I controlled substance and has been one, because it meets the statutory definition of tetrahydrocannabinols and cannot be obtained except through chemical synthesis. On May 4, 2026 the agency gave it a specific Schedule I listing and the drug code 7220. Hemp industry parties have contested that construction in litigation, but the federal enforcement position is not ambiguous. What exactly did the May 2026 DEA rule change? It amended 21 CFR 1308.11(d) by adding paragraph (115), assigning HHC the dedicated drug code 7220 instead of leaving it under the general tetrahydrocannabinols code 7370. The DEA stated the rule makes no substantive difference in HHC’s control status. The practical effect is administrative: the agency can now set production and procurement quotas and track HHC specifically. It was published at 91 FR 23913 and took effect immediately. Why did the DEA say HHC is not covered by the hemp exemption? The 2018 Farm Bill exempted hemp and the tetrahydrocannabinols in it from the Controlled Substances Act. The DEA reads that as covering what the plant makes, not what a laboratory makes from plant material. The rule states that tetrahydrocannabinols produced through chemical conversion, even when hemp derived, are considered synthetically produced. A 2024 agency letter concluded HHC does not occur naturally in cannabis and can only be obtained synthetically. What happens to hemp products on November 12, 2026? Section 781 of the appropriations law signed in November 2025 narrowed the federal hemp definition, excluding products containing cannabinoids a Cannabis sativa L. plant cannot naturally produce. A law signed September 2, 2026 moved most of those changes to December 11, 2026, but left the exclusion for non-naturally-producible cannabinoids on the original November 12 date. Under the government’s reading, HHC falls in the category that was not delayed. Is HHC the same thing as THC? It is closely related and not identical. HHC is made by adding hydrogen across a double bond in THC, a process called hydrogenation. It binds the same CB1 receptors and produces broadly comparable effects. The hydrogenation step creates a stereocenter, so commercial HHC is a mixture of two epimers that do not have equal receptor activity, which is one reason the effective dose in a given product is unpredictable. Why is product quality a concern with HHC specifically? Forensic analysis of seized material found HHC present as a mixture of two epimers at variable ratios, frequently applied to low-potency plant matter rather than present in it. The same work documented that routine analytical methods struggle to distinguish structural and stereoisomeric forms of these compounds. A label stating a milligram amount is therefore reporting a figure whose chemical identity has not been firmly established. What should a patient do if they have been using HHC? Tell your clinician what you have been using, how much, how often, and by what route, and bring the packaging if you have it. HHC acts on the same receptor as THC, so interaction review, impairment counseling, and surgical disclosure apply. Then ask what regulated options exist where you live, since the argument for switching rests on knowing the dose, not only on the legal status. Does this affect delta-8 THC and other converted cannabinoids? This particular rule addresses only hexahydrocannabinol. The legal reasoning it applies, that chemical conversion produces a synthetic substance regardless of the starting material, extends to the broader category, and the statutory hemp redefinition names synthesized and manufactured cannabinoids directly rather than relying on agency interpretation. Delta-8, delta-10, and similar compounds face the same statutory question on their own timelines. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).